Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracellular delivery of full-length antibodies via organ-targeted lipid nanoparticles.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Phosphoserine as an Alternative Energy Source for <i>E. coli</i> Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity.

ACS synthetic biology·2026
Same author

Sensory-selective Sciatic Nerve Block with 2',6' Pipecolylxylidine in an Ovine Model.

Anesthesiology·2026
Same author

Sensory-selective Peripheral and Neuraxial Nerve Blockade with 2',6'-Pipecoloxylidide: Erratum.

Anesthesiology·2026
Same author

Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice.

Science translational medicine·2026
Same author

Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy.

Nature communications·2026

Related Experiment Video

Updated: May 30, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Liposomes for HIV prophylaxis.

Nikita K Malavia1, David Zurakowski, Avi Schroeder

  • 1Laboratory for Biomaterials and Drug Delivery, Department of Anesthesiology, Division of Critical Care Medicine, Childrens Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.

Biomaterials
|August 25, 2011
PubMed
Summary
This summary is machine-generated.

New liposomal systems show promise for preventing HIV-1 infection in women. These vaginal formulations demonstrated reduced viral infection with minimal toxicity in preclinical studies, offering a potential new HIV prevention strategy.

More Related Videos

Visualization of HIV-1 Gag Binding to Giant Unilamellar Vesicle (GUV) Membranes
08:21

Visualization of HIV-1 Gag Binding to Giant Unilamellar Vesicle (GUV) Membranes

Published on: July 28, 2016

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Related Experiment Videos

Last Updated: May 30, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Visualization of HIV-1 Gag Binding to Giant Unilamellar Vesicle (GUV) Membranes
08:21

Visualization of HIV-1 Gag Binding to Giant Unilamellar Vesicle (GUV) Membranes

Published on: July 28, 2016

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Area of Science:

  • Biomedical Engineering
  • Infectious Disease Prevention
  • Nanotechnology

Background:

  • An estimated 15.7 million women globally live with HIV, with sexual intercourse being a primary transmission route.
  • Current HIV prevention methods, including vaccines and microbicides, are still under development.
  • Effective prevention strategies are crucial, especially for women, given the lack of a curative HIV treatment.

Purpose of the Study:

  • To develop and evaluate novel liposomal systems for potential vaginal application as an HIV-1 pre-exposure prophylaxis (PrEP).
  • To identify liposomal formulations with an optimal balance between anti-HIV activity and low cytotoxicity.
  • To assess the safety and tissue compatibility of these liposomal formulations in an in vivo model.

Main Methods:

  • Liposomes were formulated using various natural and synthetic lipids with diverse physicochemical properties.
  • The anti-HIV-1 efficacy of the liposomes was tested using transformed cells expressing HIV receptors.
  • Cytotoxicity was evaluated to determine the therapeutic index of each formulation.
  • In vivo safety was assessed through intra-vaginal instillation in a female mouse model.

Main Results:

  • Specific liposomal formulations demonstrated significant inhibition of HIV-1 infection in vitro.
  • The therapeutic index of the liposomes improved with increased cardiolipin content and lipid unsaturation.
  • Intra-vaginal administration of the formulations in mice showed no adverse tissue reactions, indicating benign biocompatibility.
  • Cardiolipin-based liposomes enriched with synthetic lipids exhibited promising microbicidal potential.

Conclusions:

  • Cardiolipin-based liposomes enriched with synthetic lipids represent a promising candidate for vaginal microbicides for HIV-1 prevention.
  • The developed liposomal systems offer a favorable therapeutic index and demonstrate safety in preclinical models.
  • Further development of these liposomal formulations could lead to a novel, effective strategy for HIV prevention in women.